Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Emerging life sciences companies would benefit from a bill passed by the House Oct. 11 to enhance agency flexibility in overseeing popular small business research and development programs that drive technical innovation.
The legislation, H.R. 2763, would extend agency authorities and introduce new changes under the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The programs, funded by set-asides from participating agencies’ research and development budgets for recipients outside the federal government, provide competitively awarded grants to small businesses, universities, and nonprofits. Small life science companies are among the programs’ biggest beneficiaries, according to the Biotechnology Innovation Organization, which welcomed the bill’s passage.
“Capital formation remains one of the most daunting challenges faced by new and emerging biotechnology companies, yet such companies are also the lifeblood of biomedical innovation, responsible for 70 percent of today’s clinical pipeline for new drugs and biologics,” Daniel Seaton, BIO’s director of health communications, told Bloomberg BNA in an Oct. 12 statement. Many companies rely on the programs to fund early research and establish proof of concept, he said, as well as to attract private funding.
The SBIR program requires federal agencies with research and development budgets over $100 million for nonfederal recipients to award 3.2 percent of those funds to small businesses for development of technology that can be commercialized, and the STTR program requires agencies with over $1 billion in those budgets to reserve 0.45 percent for small business awards. Eleven agencies participate in SBIR and five, including the Department of Health and Human Services, also participate in STTR. The programs provided nearly $3 billion in funding in the last fiscal year, House Science, Space, and Technology Committee Chairman Lamar Smith (R-Texas) said during debate on the bill.
Agencies provide SBIR and STTR awards in three stages: Phase 1 for research and development concept testing, Phase 2 for continued development building on Phase 1 results, and Phase 3 for commercialization. The awards can help companies bridge funding gaps between innovation concept and commercial viability.
Changes that the bill would make to the SBIR and STTR programs include:
The SBIR and STTR programs are key to supplementing private investment, said Brian Wamhoff, co-founder and head of innovation at HemoShear Therapeutics, a biotech company based in Charlottesville, Va.
“I think it’s a great thing for America and small businesses, particularly biotech,” Wamhoff told Bloomberg BNA in an Oct. 12 interview. “The combination of SBIR funding and private investment has really been key to our success.”
HemoShear has received multiple SBIR grants from five institutes within the NIH, he said, totaling nearly $20 million. The money has helped the company develop therapies for two rare and deadly metabolic disorders in children, said Wamhoff, who has testified in support of the programs before Congress.
The SBIR and STTR programs can be abused, he noted, by award recipients relying on their funding “just to stay afloat.” Some of the changes under the bill, including new agency reporting requirements, could address that concern, Wamhoff said.
There isn’t a companion bill to H.R. 2763 in the Senate at this point.
The programs were reauthorized through fiscal year 2022 under legislation signed by President Barack Obama in December.
To contact the reporter on this story: Greg Langlois in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
The bill is available at http://src.bna.com/tjN.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)